Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The development of anti-interferon antibodies may lead to treatment failure during interferon therapy. We have studied the development of such antibodies in a group of 39 haemophiliacs receiving interferon-alpha 2a for chronic hepatitis C virus (HCV) infection. Anti-interferon antibodies developed in five (13%) patients and were associated with "breakthrough hepatitis' in three cases. There was an association between the development of anti-interferon antibodies and infection with HCV genotype 3a (P = 0.01). This study suggests that the development of anti-interferon antibodies may lead to treatment failure in a proportion of haemophiliacs with HCV infection. The association with genotype 3a has not previously been reported. Monitoring for the development of breakthrough hepatitis due to anti-interferon antibodies may provide the opportunity to develop strategies to overcome their effects.

Original publication

DOI

10.1046/j.1365-2141.1996.6772294.x

Type

Journal article

Journal

Br J Haematol

Publication Date

09/1996

Volume

94

Pages

551 - 556

Keywords

Adolescent, Adult, Aged, Antibodies, Female, Hemophilia A, Hepatitis C, Humans, Interferon alpha-2, Interferon-alpha, Male, Middle Aged, Recombinant Proteins